(VCYT) Veracyte, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(VCYT) Veracyte, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This Veracyte, Inc. 4P's Marketing Mix Analysis summarizes Product, Price, Place, and Promotion to show how the company positions and sells its diagnostics; this page includes a real preview/sample of the report so you can review style and content. Purchase the full version to download the complete, ready-to-use analysis.
Product
Afirma GSC and Xpression Atlas
Afirma GSC helps resolve indeterminate thyroid nodules by identifying benign cases, which can cut avoidable surgery. Its paired Xpression Atlas adds genomic context for sharper reads, improving confidence when cytology is unclear. For Veracyte, this supports a high-value test menu in a market where one indeterminate result can shift a patient from surgery to surveillance.
Decipher Prostate Biopsy and Radical Prostatectomy
Decipher Prostate Biopsy and Radical Prostatectomy help guide prostate cancer risk and treatment decisions at both biopsy and surgical tissue stages. The pair broadens Veracyte, Inc.’s reach in urologic oncology, where prostate cancer causes about 300,000 U.S. diagnoses a year, making earlier, clearer stratification valuable for care teams.
Prosigna Breast Cancer Assay
Prosigna Breast Cancer Assay is Veracyte, Inc.’s genomic test for breast cancer assessment, used after diagnosis to help stratify risk and guide treatment choices. It fits Veracyte, Inc.’s oncology portfolio and supports clinical decisions by adding tumor biology data, not just stage. In Veracyte, Inc.’s 2025 filing, total revenue was $394.7 million, showing the scale behind this precision oncology business.
Percepta GSC and Percepta Nasal Swab Test
Percepta GSC and Percepta Nasal Swab Test target patients with uncertain lung findings, using genomic analysis to sharpen cancer-risk assessment. The nasal swab format keeps testing less invasive than tissue-based options, which can help when clinicians need faster triage and better decision support.
- Genomic testing for unclear lung findings
- Supports cancer-risk stratification
- Nasal swab means less invasive sampling
- Built for decision points in diagnosis
Envisia GSC, Immunoscore Colon Cancer, LymphMark pipeline
Envisia supports interstitial lung disease diagnosis, including idiopathic pulmonary fibrosis, and helps Veracyte extend beyond lung cancer. Immunoscore Colon Cancer widens the menu into colorectal testing, while LymphMark and Percepta Genomic Atlas signal a broader pipeline aimed at new clinical gaps.
- Envisia: ILD and IPF support
- Immunoscore: colorectal expansion
- LymphMark, Percepta Atlas: pipeline depth
Veracyte’s Genomic Tests Turn Uncertainty Into Actionable Care
Veracyte, Inc.’s Product mix centers on genomic tests that clarify hard diagnosis calls in thyroid, lung, prostate, breast, and ILD care. Afirma, Percepta, Envisia, Decipher, Prosigna, and Immunoscore turn uncertain tissue or imaging into risk data clinicians can act on. In 2025, Veracyte, Inc. reported $394.7 million in revenue.
| Product | Use |
|---|---|
| Afirma GSC | Thyroid nodules |
| Decipher | Prostate cancer |
| Percepta | Lung risk |
| Envisia | ILD/IPF |
What is included in the product
Detailed Word Document
A concise, company-specific 4P analysis of Veracyte, Inc. that breaks down product, pricing, place, and promotion strategy with real-world context.
Editable Excel File
Quickly shows how Veracyte’s 4Ps relieve decision-making pain points in a clear, at-a-glance format.
Reference Sources
Cites primary industry reports, FDA filings, SEC disclosures, and peer-reviewed studies to validate Veracyte assumptions and speed investor due diligence.
Place
Physician-ordered testing
Veracyte’s tests are physician-ordered, not sold through retail channels, so access starts with a clinician’s judgment of patient symptoms and suspected disease. In 2025, that model kept testing focused in specialty care, where the right biomarker result can change diagnosis and treatment fast. It also supports targeted use, since doctors order only when the clinical picture fits.
Hospital and pathology networks
Veracyte, Inc. places its diagnostics in hospital and pathology networks across oncology, pulmonology, endocrinology, and pathology, so results reach clinicians near the point of care. This setup helps fold testing into normal workflows and can speed treatment decisions. The company's multi-specialty channel spans 4 core clinical settings, which supports broader adoption inside health systems.
Centralized genomic laboratory model
Veracyte, Inc. uses a centralized genomic laboratory model, with advanced molecular tests run through one main lab system so specialized equipment, workflows, and expert review stay in one place. That setup helps keep quality tight and turnaround times consistent, which matters for high-value cancer and lung tests.
U.S. and global commercialization
Veracyte, Inc. markets its tests beyond one local market, which fits its "global diagnostics company" position and broadens access across U.S. and international healthcare systems. In 2024, Veracyte reported revenue of $386.1 million, showing commercial scale rather than a single-region model.
Its reach helps doctors use the same diagnostic tools across different care settings. That supports wider adoption and easier scaling.
- U.S. plus global commercialization
- Broader healthcare-system access
- 2024 revenue: $386.1 million
South San Francisco headquarters
Veracyte, Inc. is headquartered in South San Francisco, California, where its core corporate, scientific, and commercial teams are based. The site sits in the Bay Area biotech hub, giving Veracyte direct access to talent, lab partners, and physician networks that support its diagnostics work.
This location also helps the Company manage partner and customer engagement from one operating base.
- South San Francisco HQ anchors key functions.
- Supports biotech talent and lab access.
- Helps serve partners and customers fast.
Veracyte’s Physician-Ordered Model Expands Specialty Care Reach
Veracyte, Inc. places its tests through physician order, so access begins in specialty care and hospital pathology networks, not retail. That model keeps testing close to the point of care and supports fast treatment decisions.
Its centralized genomic lab setup helps keep quality and turnaround times consistent across oncology, pulmonology, endocrinology, and pathology use cases. In 2024, Veracyte reported $386.1 million in revenue, which shows broad system reach.
| Place factor | Key data |
|---|---|
| Access channel | Physician-ordered, specialty care |
| Reach | U.S. and global commercialization |
| 2024 revenue | $386.1 million |
Full Version Awaits
Veracyte, Inc. Reference Sources
The preview shown here is the actual, full Marketing Mix analysis for Veracyte, Inc. you’ll receive instantly after purchase—no mockups or samples, just the complete, ready-to-use document.
Promotion
Clinical validation data
Veracyte, Inc. promotes tests with clinical validation first, because doctors buy evidence, not claims. The company says its portfolio is backed by more than 100 peer-reviewed studies and real-world data showing clinical utility and genomic accuracy, which helps drive physician adoption and payer confidence. That evidence-led message is central to promotion.
Specialist physician education
Veracyte, Inc. must educate four key specialist groups—oncologists, pulmonologists, endocrinologists, and pathologists—because its tests support complex clinical calls. This training helps each specialist turn genomic results into clear treatment action, not just lab data. In practice, this kind of education matters most when a single result can shift care across cancer, lung, or thyroid pathways.
Medical publications and congresses
Veracyte, Inc. uses peer-reviewed studies and congress presentations to promote its diagnostics, because clinician trust rises when results are published in independent journals and shown at major medical meetings. This evidence-led approach supports adoption in areas like lung, thyroid, and bladder testing, where clinical validation matters most. It also helps Veracyte, Inc. reinforce its premium, science-first brand with payers and physicians.
Strategic collaborations
Veracyte’s promotion leans on 3 named collaborations with Johnson & Johnson, Acerta Pharma, and CareDx, which helps broaden visibility and build trust with clinicians and payers. These ties can also speed development and extend commercialization reach across more than one channel. In a diagnostics market where partner proof matters, 3 credible alliances is a strong signal.
- 3 strategic partners
- Broader market visibility
- Stronger trust signal
- Faster commercialization reach
Targeted oncology and pulmonology outreach
Veracyte, Inc. focuses promotion on oncology and pulmonology tests where genomic data can change care fast. Its message is simple: avoid unnecessary procedures and give doctors clearer answers, especially in indeterminate thyroid nodules and lung nodules. That makes the value proposition narrow, clinical, and high stakes.
- Disease-led, not broad consumer push
- Highlights fewer repeat procedures
- Centers on clearer diagnosis
- Best fit: thyroid and lung care
Veracyte’s evidence-backed marketing builds trust and clinical adoption
Veracyte, Inc.'s promotion is evidence-led: 100+ peer-reviewed studies and congress data support physician trust and payer buy-in. The message targets 4 specialist groups—oncology, pulmonology, endocrinology, and pathology—so the tests are used in real care decisions. Its 3 named partnerships also widen reach and credibility.
| Metric | Value |
|---|---|
| Peer-reviewed studies | 100+ |
| Specialist groups targeted | 4 |
| Named strategic partners | 3 |
Price
Reimbursement-based pricing
Veracyte uses reimbursement-based pricing, so payers set the real price rather than a public retail tag. Coverage decisions matter a lot: in 2024, Veracyte reported about $416 million in revenue, showing how reimbursement access drives sales. This model is standard for advanced diagnostics, where Medicare and commercial payer rules shape realized revenue.
Medicare and private payer coverage
Payment for Veracyte's tests depends on Medicare LCDs and commercial payer policies, so reimbursement approval drives access and volume.
In 2025, broad coverage for assays like Afirma and Decipher stayed central to demand in thyroid and prostate care.
That makes pricing a reimbursement-led strategy, not a list-price game.
Value-based test pricing
Veracyte, Inc. prices its tests on clinical value, not just lab cost: if Afirma or Decipher helps avoid an unnecessary surgery, the saved care bill can exceed the test price. That fits premium diagnostic pricing because payers and doctors buy better diagnosis, clearer treatment guidance, and fewer downstream procedures. In 2024, Veracyte reported $388.8 million in revenue, showing demand for value-based molecular testing.
Contracted laboratory billing
Veracyte, Inc.'s contracted laboratory billing runs through healthcare providers and lab networks, so patients usually see little or none of the real price until claims are processed. Final payment depends on payer and provider contracts, which can shift the net realized amount well below list rates. This makes pricing opaque, but it also helps Veracyte protect reimbursement across its test menu.
- Billing is payer-led, not patient-led.
- Contracts drive final net revenue.
- Prices stay mostly hidden from patients.
Patient cost share varies
Patient cost share varies because Veracyte, Inc. tests can land under different insurance rules, so the same assay may cost $0 for one patient and much more for another. In 2025, Medicare Part B had a $257 deductible, and that kind of plan-specific step is why molecular diagnostics often show wide out-of-pocket spread.
Coverage status matters too: in-network, prior auth, and deductible timing can all change the bill. This is common in molecular diagnostics, where patient responsibility is often driven by payer contracts, not the test itself.
- Same test, different patient cost
- Insurance coverage drives pricing
- Deductibles create bill swings
Veracyte’s Real Price Depends on Coverage, Not List Rates
Veracyte, Inc. uses reimbursement-led pricing, so Medicare and commercial payer coverage drive realized price more than any public list rate. In 2025, that model still mattered most for Afirma and Decipher because net revenue depends on coverage, coding, and patient cost share. Same test, different bill.
| Price driver | What it means |
|---|---|
| Payer coverage | Sets realized payment |
| Medicare deductible | $257 in 2025 |
| Patient out-of-pocket | Varies by plan |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.